Comparative Pharmacology
Head-to-head clinical analysis: JENCYCLA versus VIORELE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JENCYCLA versus VIORELE.
JENCYCLA vs VIORELE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JENCYCLA (sodium phenylbutyrate and ursodoxicoltaurine) is a fixed-dose combination. Sodium phenylbutyrate is a nitrogen-binding agent that conjugates with glutamine to form phenylacetylglutamine, which is excreted renally, reducing ammonia levels. Ursodoxicoltaurine is a hydrophilic bile acid that replaces toxic bile salts, reduces hepatocyte apoptosis, and improves bile flow.
VIORELE is a monoclonal antibody that binds to and inhibits the activity of interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in the pathogenesis of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
1-2 mg/kg IV once daily every 3-4 weeks; maximum dose 100 mg.
50 mg orally once daily
None Documented
None Documented
8-12 hours; prolonged to 24 hours in severe hepatic impairment
Terminal elimination half-life of 12–15 hours (mean 13.5 h) in healthy adults; may be prolonged in renal impairment (up to 30 h).
Renal: 35-45% unchanged; biliary/fecal: 50-60% as metabolites
Primarily renal (unchanged drug and metabolites, ~60%) and fecal (~30%), with minor biliary contribution (~10%).
Category C
Category C
Oral Contraceptive
Oral Contraceptive